EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PRIOR EXPOSURE TO BIOLOGIC THERAPY: SUBANALYSIS FROM THE PHASE 2 LATTICE-UC STUDY
Stefan Schreiber 1
Nicholas Powell 2
Florian Rieder 3
Anita Afzali 4
Yi Luo 5
Mark T. Osterman
Chun Wu
Lisu Wang
Courtney Radosti
Aditya Patel
1 University Hospital Schleswig-Holstein, Kiel, Germany
2 Imperial College London, London, United Kingdom
3 Digestive Diseases and Surgery Institute Cleveland Clinic, Cleveland, United States
4 The Ohio State University Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology, and Nutrition, Columbus, United States
5 Bristol Myers Squibb, Princeton, United States
Topic
IBD, Nurses, Primary Care
Conference
UEG Week 2022
Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]